Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
-- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142)…
Jinsha Site Museum Draws 120,000 Visitors During the National Day Holiday with Its Widely Praised ‘Qing Rhythm: An Invitation from Jinsha’ Event
CHENGDU, China, Oct. 15, 2025 /PRNewswire/ -- A news report from CRI…
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025
- Presentations highlight clinically meaningful reductions in BMI in patients with acquired…
Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
July 09, 2025 16:16 ET | Source: Rhythm Pharmaceuticals, Inc. BOSTON, July…
